KRON_OUT_1 [2025-04-14 13:57:56 -0400] 3243 Bytes | 887 tokens | Cum: 887 tkns (11.09% of 8k)
==========================================================================

We're scouting for winners today. Its 1:57:55 PM on Mon Apr 14, 2025 -0400 and I'm looking at Kronos Bio (KRON) up to 0.8399 from 0.7800

Help me investigate to see if its got potential or just another dud. So, I pulled together a bunch of data for you to look over real fast.

--- COMPANY PROFILE ---
Company: Kronos Bio (KRON)
IPO: 2020-10-09 (4 Years Ago)
Market Cap: $51,043,426
Shares Outstanding: 60,970,000
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XNAS
Description: Kronos Bio Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery and development of small molecule therapeutics to address deregulated transcription, a hallmark of cancer and autoimmune diseases.

Here’s the first list of news for Kronos Bio:

C1 - Mar-18-25 04:01PM - Kronos Bio Reports Fourth Quarter and Full Year 2024 Financial Results
C2 - Nov-28-24 11:50AM - Kronos Bio announces interim CEO and workforce cuts of 83%
C3 - Nov-27-24 08:59AM - Kronos Bio Shakes Up Leadership - Cuts 83% Of Workforce Amid Strategic Overhaul
C4 - Nov-27-24 08:59AM 07:30AM - Kronos Bio Announces CEO Transition and Reduction in Force
C5 - Nov-27-24 08:59AM 05:38AM - Kronos, Idorsia plan layoffs; PTC shelves ALS drug
C6 - Nov-14-24 04:02PM - Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024
C7 - Nov-14-24 04:02PM 01:24PM - Kronos mulls strategic alternatives after axing cancer drug development
C8 - Nov-13-24 05:30PM - Kronos Bio, Inc. (KRON) Reports Q3 Loss, Tops Revenue Estimates

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**. I am **ScanScor**, a unified document retrieval and report parser.
Your role is to examine all available company data and draw sound conclusions.
The company under analysis is: Kronos Bio (KRON).

2) To request information, refer to any listed documents using their reference codes.

3) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
At the end, you'll be prompted to return these data pairs:

1) BRIEF_SUMMARY[] -- Write a brief summary
2) MARKET_SCORE[] -- Assign a Market Score
3) PRICE_TARGET[] -- Set a price target
4) AI_RPT_HEADLINE[] -- Generate a headline for the article
5) SQUEEZE_POTENTIAL[] -- Potential for this stock to become an active short squeeze play
6) TAGS[] -- 1 to 4 words for SEO tags
7) STOCK_TYPE[] -- Describe the type of investor style suited to this stock
8) PRIMARY_CATALYST[] -- What you believe caused this stock to move today
9) SENTIMENT[] -- Mkt sentiment of the opportunity
10) IMPROVEMENT_SUGGESTION[] -- What can we do better
11) ETHICAL_RATING[] -- Rate alignment with long-term shareholder interests

Restrict the next response to just 3 tokes until it's time for the summary and data pairs at the end.
Request a document with its reference code(s), such as:
- `C1`, `C2`, `C3`, etc.
- To load more documents, reply with: `NEX`

News articles, SEC filings, and key metrics will be revealed in subsequent prompts.
Stay focused. Gather evidence. Continue until your conclusions are clear.

KRON_OUT_3 [2025-04-14 13:57:57 -0400] 1098 Bytes | 280 tokens | Cum: 1170 tkns (14.62% of 8k)
==========================================================================

Showing C2 (chunk 1 of 4): C2:
**Kronos Bio announces interim CEO and workforce cuts of 83%**
Date: Nov-28-24 11:50AM
Source: (Pharmaceutical Technology)
URL: https://finance.yahoo.com/m/9ca3acac-ab5a-3004-ab22-ddabdc6c1c7e/kronos-bio-announces-interim.html

Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Kronos Bio has announced the appointment of Deborah Knobelman as president and interim chief executive officer, effective from 3 December 2024.

Dr Knobelman will also become principal executive and financial and accounting officer.

The company has also disclosed a significant workforce reduction, aiming to cut 83% of its employees by the end of 2024.

The decision is part of Kronos Bio's ongoing strategy to reduce costs while evaluating different options to enhance stockholder value. These options may include potential business combinations or the divestiture of its internally developed

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

KRON_OUT_5 [2025-04-14 13:57:58 -0400] 656 Bytes | 192 tokens | Cum: 1364 tkns (17.05% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-04T15:44:49Z - Short Interest in Kronos Bio, Inc. (NASDAQ:KRON) Drops By 13.4%...
A2 - 2025-03-19T20:16:25Z - Kronos Bio (NASDAQ:KRON) Issues Earnings Results...
A3 - 2025-03-18T20:17:11Z - Kronos Bio Reports Fourth Quarter and Full Year 2024 Financial Results...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

KRON_OUT_7 [2025-04-14 13:57:58 -0400] 1098 Bytes | 340 tokens | Cum: 1706 tkns (21.32% of 8k)
==========================================================================

Showing A1 (chunk 1 of 5): A1:
**Short Interest in Kronos Bio, Inc. (NASDAQ:KRON) Drops By 13.4%**Date: 2025-04-04Source: {'uri': 'marketbeat.com', 'dataType': 'news', 'title': 'Market Beat'}URL: https://www.marketbeat.com/instant-alerts/short-interest-in-kronos-bio-inc-nasdaqkron-drops-by-134-2025-04-02/Kronos Bio, Inc. (NASDAQ:KRON - Get Free Report) was the target of a large decline in short interest in March. As of March 15th, there was short interest totalling 748,000 shares, a decline of 13.4% from the February 28th total of 863,500 shares. Currently, 1.9% of the company's stock are sold short. Based on an average daily volume of 231,500 shares, the short-interest ratio is currently 3.2 days.

Shares of KRON traded up $0.02 on Wednesday, hitting $0.83. The company's stock had a trading volume of 15,676 shares, compared to its average volume of 187,348. The firm has a market capitalization of $50.67 million,

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

KRON_OUT_9 [2025-04-14 13:57:59 -0400] 1032 Bytes | 321 tokens | Cum: 2029 tkns (25.36% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2024-10-23T12:55:00Z - Kronos Bio Data Presentation at EORTC-NCI-AACR Symposium Highlights the Importance of p300 KAT Inhibition in HPV-Driven Tumors
B2 - 2024-10-07T12:55:00Z - Kronos Bio Announces Selection of Autoimmune Development Candidate for Sjögren’s Disease
B3 - 2024-08-08T21:45:09Z - 10x Genomics (TXG) Reports Q2 Loss, Tops Revenue Estimates
B4 - 2024-05-23T21:15:00Z - Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
B5 - 2024-05-22T20:30:00Z - Kronos Bio to Participate in Three Upcoming Healthcare Conferences and Events
B6 - 2024-05-21T12:15:00Z - Kronos Bio Appoints Deborah Knobelman, Ph.D. as Chief Operating Officer and Chief Financial Officer 

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

KRON_OUT_11 [2025-04-14 13:58:00 -0400] 817 Bytes | 245 tokens | Cum: 2276 tkns (28.45% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Kronos Bio Data Presentation at EORTC-NCI-AACR Symposium Highlights the Importance of p300 KAT Inhibition in HPV-Driven Tumors**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2024/10/23/2967816/0/en/Kronos-Bio-Data-Presentation-at-EORTC-NCI-AACR-Symposium-Highlights-the-Importance-of-p300-KAT-Inhibition-in-HPV-Driven-Tumors.htmlKronos Bio presented preclinical data showing that its p300 KAT inhibitor, KB-9558, can suppress the expression of HPV oncogenes E6 and E7, leading to the restoration of tumor suppressor pathways and anti-tumor effects in HPV-driven tumors.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

KRON_OUT_13 [2025-04-14 13:58:01 -0400] 1066 Bytes | 297 tokens | Cum: 2583 tkns (32.29% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-03-18 10-K ITEM 7. MGT DISC & ANALYSIS OF FIN COND & RESULTS OF OPER

The following discussion and analysis should be read in conjunction with our financial statements and related notes included elsewhere in this Annual Report on Form 10-K. This discussi...

S2 - 2025-03-18 8-K Item 2.02 Results of Oper and Fin Cond

On March 18, 2025, Kronos Bio, Inc. (the Company) issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2024. A copy of the press release is being furnished as Exhibit 9...

S3 - 2024-11-13 10-Q PART 1. FIN INFO

ITEM 1. COND FIN STATEMENTS

KRONOS BIO, INC.

Condensed Balance Sheets

(Unaudited)

(in thousands, except per share amounts)

September 30, 2024 December 31, 2023 Assets Curr assets: Cash and cash equiv $ 74,964 $ 64,326...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

KRON_OUT_15 [2025-04-14 13:58:01 -0400] 1098 Bytes | 229 tokens | Cum: 2814 tkns (35.17% of 8k)
==========================================================================

Showing S1 (chunk 1 of 6): S1:
ITEM 7. MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis should be read in conjunction with our financial statements and related notes included elsewhere in this Annual Report on Form 10-K. This discussion contains forward-looking statements that reflect our plans, estimates and beliefs and involve numerous risks and uncertainties, including but not limited to those described in the Risk Factors section of this Annual Report. Actual results may differ materially from those contained in any forward-looking statements. You should carefully read Forward-Looking Statements and Risk Factors.

Overview

We are a biopharmaceutical company that has historically focused on the discovery and development of small molecule therapeutics that address deregulated transcription, a hallmark of cancer and autoimmune disease.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

KRON_OUT_17 [2025-04-14 13:58:03 -0400] 1098 Bytes | 246 tokens | Cum: 3062 tkns (38.27% of 8k)
==========================================================================

Showing S1 (chunk 2 of 6):

In November 2024, we announced our decision to discontinue our clinical trial of istisociclib, our lead asset. Based on a review of emerging adverse events in the 80mg four-days-on, three-days-off expansion cohort of our Phase 1/2 clinical trial for istisociclib and an overall review of our business, we determined that the benefit-risk profile does not warrant further clinical evaluation.

Considering the discontinuation of our istisociclib program and the clinical development timelines of our additional pipeline candidates, in November 2024 our board of directors retained an independent financial advisor to initiate a formal process to evaluate potential strategic alternatives focused on maximizing stockholder value, including, but not limited to, an acquisition, merger, reverse merger or other business combination, sales of assets, or other strategic transactions. If we do not succ

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

KRON_OUT_19 [2025-04-14 13:58:11 -0400] 5695 Bytes | 1516 tokens | Cum: 4580 tkns (57.25% of 8k)
==========================================================================

This is our set of metrics for Kronos Bio.
Please analyze the numbers.

+---------------------+-----------------------+-------------------------+-----------------------+
| Volume: 62,043 | Perf Month: -11.30% | Option/Short: Yes / Yes | Sales Y/Y TTM: 56.62% |
+---------------------+-----------------------+-------------------------+-----------------------+
| Avg Volume: 181.35K | Perf Quarter: -12.26% | Short Float: 1.56% | ROE: -69.80% |
+---------------------+-----------------------+-------------------------+-----------------------+
| Rel Volume: 0.52 | Index: - | Short Ratio: 3.37 | ROI: -78.91% |
+---------------------+-----------------------+-------------------------+-----------------------+
| RSI (14): 47.27 | Market Cap: 50.84M | Short Interest: 0.61M | Sales Surprise: - |
+---------------------+-----------------------+-------------------------+-----------------------+
| ATR (14): 0.05 | Shs Outstand: 60.46M | Beta: 1.75 | EPS Surprise: - |
+---------------------+-----------------------+-------------------------+-----------------------+
| SMA20: 0.75% | Shs Float: 39.23M | Sales Q/Q: -0.70% | P/E: - |
+---------------------+-----------------------+-------------------------+-----------------------+
| SMA50: -8.73% | Inst Own: 23.43% | Sales past 5Y: 11.32% | Earnings: Mar 18 AMC |
+---------------------+-----------------------+-------------------------+-----------------------+
| SMA200: -16.36% | Insider Own: 35.66% | Employees: 10 | |
+---------------------+-----------------------+-------------------------+-----------------------+
| Perf Week: 8.22% | Insider Trans: 0.00% | Debt/Eq: 0.28 | |
+---------------------+-----------------------+-------------------------+-----------------------+

The next section covers any insider trading by Kronos Bio officers or majority shareholders (if available).

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 9848000.0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -86079000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 0.8399
Average Volume: 143229.24
30-Day High: 0.9488
30-Day Low: 0.7545

[Detailed Financials: TTM 2024]
- Total Assets: $124,363,000.0
- Total Liabilities: $36,783,000.0
- Total Equity: $87,580,000.0
- Current Assets: $115,228,000.0
- Current Liabilities: $15,277,000.0

[Income Statement: TTM 2024]
- Revenue: $9,848,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -1.43

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $20,245,000.0

[Detailed Financials: FY 2024]
- Total Assets: $124,363,000.0
- Total Liabilities: $36,783,000.0
- Total Equity: $87,580,000.0
- Current Assets: $115,228,000.0
- Current Liabilities: $15,277,000.0

[Income Statement: FY 2024]
- Revenue: $9,848,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -1.43

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $20,245,000.0
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of Kronos Bio (KRON).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about Kronos Bio.

2) MARKET_SCORE[]
This conversation was initiated because KRON is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for KRON.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, KRON could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect KRON to increase 50% from its current price of $0.84, say: PRICE_TARGET[1.26]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of Kronos Bio.

11) ETHICAL_RATING[]
Rate Kronos Bio’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

Return only: FIELD[value] for each of the above 11 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

KRON_IN_21 [2025-04-14 13:58:11 -0400] 126 Bytes | 29 tokens | Cum: 4783 tkns (59.79% of 8k)
==========================================================================

====================================
[2025-04-14 13:58:11] # Analysis Completed
Elapsed Time: 16.40 seconds